Aptevo Therapeutics APVO Stock
Aptevo Therapeutics Price Chart
Aptevo Therapeutics APVO Financial and Trading Overview
| Aptevo Therapeutics stock price | 1.99 USD |
| Previous Close | 1.59 USD |
| Open | 1.64 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 900 |
| Day's Range | 1.58 - 1.64 USD |
| 52 Week Range | 1.49 - 7.2 USD |
| Volume | 43.4K USD |
| Avg. Volume | 51.07K USD |
| Market Cap | 11.66M USD |
| Beta (5Y Monthly) | 5.307042 |
| PE Ratio (TTM) | 0.49382716 |
| EPS (TTM) | -87.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.5 USD |
APVO Valuation Measures
| Enterprise Value | -7820707 USD |
| Trailing P/E | 0.49382716 |
| Forward P/E | -0.3258656 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | Infinity |
| Price/Book (mrq) | 0.49813202 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 0.261 |
Trading Information
Aptevo Therapeutics Stock Price History
| Beta (5Y Monthly) | 5.307042 |
| 52-Week Change | -54.022% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 7.2 USD |
| 52 Week Low | 1.49 USD |
| 50-Day Moving Average | 1.73 USD |
| 200-Day Moving Average | 2.4 USD |
APVO Share Statistics
| Avg. Volume (3 month) | 51.07K USD |
| Avg. Daily Volume (10-Days) | 45.54K USD |
| Shares Outstanding | 7.29M |
| Float | 7.2M |
| Short Ratio | 1.07 |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 13.31% |
| Shares Short | 51.1K |
| Short % of Float | 0.70% |
| Short % of Shares Outstanding | 0.69% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:14 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -48.011% |
| Return on Equity (ttm) | 192.44% |
Income Statement
| Revenue (ttm) | 0 USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 3.11M USD |
| EBITDA | -29949000 USD |
| Net Income Avi to Common (ttm) | 16.72M USD |
| Diluted EPS (ttm) | 3.24 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 25.33M USD |
| Total Cash Per Share (mrq) | 3.47 USD |
| Total Debt (mrq) | 5.92M USD |
| Total Debt/Equity (mrq) | 25.44 USD |
| Current Ratio (mrq) | 4.914 |
| Book Value Per Share (mrq) | 3.212 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -11339000 USD |
| Levered Free Cash Flow (ttm) | -28853250 USD |
Profile of Aptevo Therapeutics
| Country | United States |
| State | WA |
| City | Seattle |
| Address | 2401 4th Avenue |
| ZIP | 98121 |
| Phone | 206 838 0500 |
| Website | https://www.aptevotherapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 45 |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Q&A For Aptevo Therapeutics Stock
What is a current APVO stock price?
Aptevo Therapeutics APVO stock price today per share is 1.99 USD.
How to purchase Aptevo Therapeutics stock?
You can buy APVO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aptevo Therapeutics?
The stock symbol or ticker of Aptevo Therapeutics is APVO.
Which industry does the Aptevo Therapeutics company belong to?
The Aptevo Therapeutics industry is Biotechnology.
How many shares does Aptevo Therapeutics have in circulation?
The max supply of Aptevo Therapeutics shares is 1.46M.
What is Aptevo Therapeutics Price to Earnings Ratio (PE Ratio)?
Aptevo Therapeutics PE Ratio is now.
What was Aptevo Therapeutics earnings per share over the trailing 12 months (TTM)?
Aptevo Therapeutics EPS is -87.38 USD over the trailing 12 months.
Which sector does the Aptevo Therapeutics company belong to?
The Aptevo Therapeutics sector is Healthcare.
Aptevo Therapeutics APVO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Capital Market Composite RCMP | 96.46 USD — |
-4.76
|
— — | 95.94 USD — | 97.68 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}